A study just published in European Urology has suggested that early therapy with Prostvac-type vaccines might have value in the management of men with a rising PSA after first-line therapy. The key details of this small, 40-patient study are provided in the abstract of the paper by DiPaolo et al. The study itself was complex […]Image may be NSFW.
Clik here to view.
Clik here to view.
